EDITOR’S NOTE: We want to bring you this update via iCopyright, but have no control over their ads. Please know that GNN does not endorse the advertisements… Thank you.
The final round of clinical trials for MDMA assisted psychotherapy is kicking off in Vancouver, leading the way for Canada and the United States to approve the drug for therapeutic use as early as 2021.
The third and final phrase of trials gets underway after the Food and Drug Administration (FDA) designated MDMA as a “breakthrough therapy” for post-traumatic stress disorder (PTSD) in August 2017, ensuring that it will work with advocates to complete the last phase quickly.
Traditional PTSD treatments can last years or as long as a lifetime and focus on desensitization, which can cause pain. Even more, just 10 to 15 percent of people actually recover, and there’s a high drop-out rate, Mark Haden a public health professor at the University of British Columbia told Canada’s CTV News. On the other hand, MDMA-assisted therapy usually lasts fewer than four months and two-thirds of participants didn’t have PTSD one year after treatment, he told the news outlet.
The therapy consists of three eight hour sessions in…
The post “Breakthrough Therapy” For PTSD Enters Final Round of Trials After Amazing Results appeared first on FeedBox.